Compare Aspen Aerogels Inc (ASPN) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aspen Aerogels Inc vs Boston Scientific Corporation — how do they compare? Aspen Aerogels Inc trades at $5.25 (market cap $427.65M), while Boston Scientific Corporation trades at $45 (market cap $66.54B). The key difference: Boston Scientific Corporation is far larger — about 155.6× Aspen Aerogels Inc's market cap, and Aspen Aerogels Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| ASPN | BSX | |
|---|---|---|
Market Cap | $427.65M | $66.54B |
Sector | Technology | Health |
52-Week High | $8.82 | $108.14 |
52-Week Low | $2.57 | $42.68 |
Enterprise Value | $382.60M | $76.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASPN trades at $5.16, down 1.53% on the day, with a bearish technical signal despite oversold RSI readings. The company reported a Q1 2026 loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility. Financials show significant net losses but improving cash flow trends into 2026.
Outlook remains challenging with persistent losses and negative margins, though analyst consensus is strongly bullish (83% buy ratings). Key risks include execution on facility restarts and EV demand volatility. The stock offers high-risk growth potential if operational improvements and electrification trends accelerate profitability.
Boston Scientific (BSX) trades at $44.77, down 0.49% with a bearish technical signal despite strong fundamentals. The company shows robust revenue growth from $12.7B in 2022 to $20.1B in 2025, with net income margin expanding to 17.29%. Recent earnings beats and a 88% analyst buy rating contrast with the stock's 60% decline from its 2025 high, creating a significant valuation gap versus the $72.38 consensus target.
BSX presents a compelling value opportunity with attractive valuation metrics (P/E 18.73, P/S 3.25) and strong profitability, though investors face near-term technical weakness and competitive pressures in key segments like electrophysiology. The stock's current price represents a 38% discount to analyst targets, suggesting substantial upside potential for patient investors despite recent market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
